| 1. |
Jaffe ES, Harris NL, Stein H,et al. World Health Organization classification of tumors pathology and genetics of tumors of haematopoietic and lymphoid tissues. Lyon, France: International Agency for Research on Cancer. 2001.
|
| 2. |
Plosker GL, Figgitt DP. Rituximab: a review of its use in non-Hodgkin‘s lymphoma and chronic lymphocytic leukaemia. Drugs, 2003; 63(8): 803-843.
|
| 3. |
Guyatt GH, Rennie D, Editors, The Evidence-Based Medicine Working Group. Users’ Guides to the Medical Literature: A Manual for Evidence-Based Clinical Practice. Chicago: AMA Press. 2002.
|
| 4. |
Schulz H, Bohl ius JF, Trelle S,et al.Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst, 2007, 99(9): 706-714.
|
| 5. |
Marcus R, Imrie K, Belch A, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood, 2005; 105(4): 1417-1423.
|
| 6. |
Hiddemann W, Kneba M, Dreyling M,et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin,vincristine,and prednisone(CHOP)significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone:results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood, 2005, 106(12): 3725-3732.
|
| 7. |
Ogura M, Morishima Y, Kagami Y, et al. Randomized phase II study of concurrent and sequential rituximab and CHOP chemotherapy in untreated indolent B-cell lymphoma. Cancer Sci, 2006, 97(4): 305-312.
|
| 8. |
Forstpointner R, Dreyl ing M, Repp R, et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas:results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood, 2004, 104(10): 3064-3071.
|
| 9. |
Herold M, Haas A, Srock S,et al. Rituximab added to first-line mitoxantrone,chlorambucil,and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study.J Clin Oncol,2007,25(15):1986-1992.
|
